Rhizome AI
Rhizome AI gives regulatory teams quick, plain-English access to critical FDA and EMA data. It uses a generative AI-based regulatory intelligence platform that ingests and organizes data from Drugs@FDA, EPARs, CTIS and other regulatory sources to produce structured summaries with verified sources. The system continually refreshes datasets to ensure up-to-date information for decision-making. Target customers are Regulatory Affairs professionals in pharma, from individuals to large enterprises, with tiered plans and integrations for data access. The product is a B2B SaaS solution designed to scale regulatory research and improve decision-making for drug development and regulatory work.
Rhizome AI
Rhizome AI gives regulatory teams quick, plain-English access to critical FDA and EMA data. It uses a generative AI-based regulatory intelligence platform that ingests and organizes data from Drugs@FDA, EPARs, CTIS and other regulatory sources to produce structured summaries with verified sources. The system continually refreshes datasets to ensure up-to-date information for decision-making. Target customers are Regulatory Affairs professionals in pharma, from individuals to large enterprises, with tiered plans and integrations for data access. The product is a B2B SaaS solution designed to scale regulatory research and improve decision-making for drug development and regulatory work.